Linezolid
Based on 54 publication(s) in Google Scholar
Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 165800-03-3
- Formula: C16H20FN3O4
- Molecular Weight:337.35
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Linezolid
More- Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]
- Acta Pharm Sin B. 2017, 52(6): 971-976.
- Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Pharmaceutics. 2020 Nov 21;12(11):1126. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Virulence. 2024 Dec;15(1):2415952. [Abstract]
- Microb Biotechnol. 2021 Nov;14(6):2538-2551. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Drug Des Devel Ther. 2018 Jun 11:12:1679-1684. [Abstract]
- Bioorg Chem. 2026 Mar:170:109493. [Abstract]
- Int J Antimicrob Agents. 2025 Jun;65(6):107470. [Abstract]
- Microb Genom. 2026 May;12(5):001723. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- mLife. 2025 Apr 15;4(2):155-168. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0094524. [Abstract]
- Front Microbiol. 2023 Apr 26:14:1131178. [Abstract]
- Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0165522. [Abstract]
- Antimicrob Agents Chemother. 2021 Mar 18;65(4):e01445-20. [Abstract]
- Front Microbiol. 2020 Feb 14;11:196. [Abstract]
- Front Microbiol. 2018 Sep 7:9:2095. [Abstract]
- ACS Omega. 2025 Oct 27;10(44):52289-52295. [Abstract]
- ACS Omega. 2023 Mar 6;8(10):9652-9661. [Abstract]
- ACS Omega. 2023 Feb 3;8(6):5415-5425. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- iScience. 2023 Mar 11;26(4):106378. [Abstract]
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- ACS Infect Dis. 2026 Feb 13;12(2):623-636. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1473-1485. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- ACS Infect Dis. 2024 Aug 9;10(8):2961-2977. [Abstract]
- Microbiol Spectr. 2024 Apr 2;12(4):e0389423. [Abstract]
- ACS Infect Dis. 2023 Dec 8;9(12):2523-2537. [Abstract]
- Microbiol Spectr. 2022 Apr 27;10(2):e0054121. [Abstract]
- Microbiol Spectr. 2022 Feb 23;10(1):e0099121. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Microb Pathog. 2020 Feb;139:103866. [Abstract]
- Thromb Res. 2025 Sep 22:255:109498. [Abstract]
- Dis Model Mech. 2021 Dec 1;14(12):dmm049145. [Abstract]
- Infect Drug Resist. 2021 Dec 16;14:5449-5456. [Abstract]
- J Antibiot (Tokyo). 2025 Oct 9. [Abstract]
- Eur J Clin Pharmacol. 2021 Jan;77(1):79-86. [Abstract]
- J Antibiot. 2020 Dec;73(12):845-851. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Rapid Commun Mass Spectrom. 2025;39(20):e10103. [Abstract]
- Biol Pharm Bull. 2022;45(4):421-428. [Abstract]
- Pol J Microbiol. 2023 Jun 14;72(2):199-208. [Abstract]
- Res Sq. 2026 Apr 6.
- SSRN. 2025 Nov 15.
- bioRxiv. 2025 Oct 12.
- Authorea. 2025 Sep 17.
- Research Square Preprint. 2024 Nov 13.
- Research Square Preprint. 2020 Jun.
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
WB
All Antibiotic Isoforms
More
Biological Activity
|
Oxazolidinone |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
105.4 μM
Compound: linezolid
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| H9c2 | IC50 |
16.9 μg/mL
Compound: Linezolid
|
Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay
|
[PMID: 38505856] |
| H9c2 | IC50 |
7.98 μM
Compound: Linezolid
|
Inhibition of mitochondrial protein synthesis in rat H9c2 cells measured after 5 days by ELISA
Inhibition of mitochondrial protein synthesis in rat H9c2 cells measured after 5 days by ELISA
|
[PMID: 32666789] |
| H9c2 | IC50 |
8.71 μM
Compound: Linezolid
|
Inhibition of mitochondrial protein synthesis in rat H9c2 cells after 5 days by In-Cell ELISA
Inhibition of mitochondrial protein synthesis in rat H9c2 cells after 5 days by In-Cell ELISA
|
[PMID: 28523106] |
| HEK293-A | IC50 |
215 μg/mL
Compound: 1; LZN
|
Cytotoxicity against HEK293A cells after 48 hrs by MTT assay
Cytotoxicity against HEK293A cells after 48 hrs by MTT assay
|
10.1039/C5MD00101C |
| HeLa | IC50 |
>100 μg/mL
Compound: Linezolid
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 17456595] |
| HeLa | IC50 |
>400 μg/mL
Compound: Linezolid
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| Hepatocyte | IC50 |
17 μM
Compound: 1 (Linezolid)
|
Compound was evaluated for inhibition of Mono aminoxidase B in rat primary hepatocytes
Compound was evaluated for inhibition of Mono aminoxidase B in rat primary hepatocytes
|
[PMID: 12127518] |
| HepG2 | EC50 |
>30 μM
Compound: Linezolid
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by CellTiter-Glo assay
|
[PMID: 31383589] |
| HepG2 | IC50 |
>25 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30553735] |
| HepG2 | IC50 |
>25 μM
Compound: 1; Zyvox
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30218910] |
| HepG2 | IC50 |
>25 μM
Compound: Linezolid
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31654879] |
| HepG2 | IC50 |
>30 μM
Compound: Linezolid
|
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 38761790] |
| HepG2 | IC50 |
>64 μM
Compound: Linezolid
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
|
[PMID: 31676225] |
| L02 | IC50 |
213 μg/mL
Compound: 1; LZN
|
Cytotoxicity against human L02 cells after 48 hrs by MTT assay
Cytotoxicity against human L02 cells after 48 hrs by MTT assay
|
10.1039/C5MD00101C |
| MG-63 | IC50 |
>400 μg/mL
Compound: Linezolid
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| MRC5 | IC50 |
>400 μg/mL
Compound: LIN
|
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38784477] |
| NIH3T3 | IC50 |
465 μg/mL
Compound: Linezolid
|
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
|
[PMID: 19819597] |
| Osteoblast | IC50 |
>400 μg/mL
Compound: Linezolid
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
[PMID: 17088489] |
| Osteoblast | IC50 |
>400 μg/mL
Compound: Linezolid
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| THP-1 | EC50 |
0.18 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP-1 cells at pH 5.5 after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP-1 cells at pH 5.5 after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.29 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.35 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.4 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.47 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.62 mg/L
Compound: Linezolid
|
Antimicrobial activity against Listeria monocytogenes infected in THP1 cells after 24 hrs
Antimicrobial activity against Listeria monocytogenes infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.63 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.63 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.63 mg/L
Compound: Linezolid
|
Antimicrobial activity against Staphylococcus aureus infected in THP1 cells after 24 hrs
Antimicrobial activity against Staphylococcus aureus infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.7 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
0.84 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
2.78 mg/L
Compound: Linezolid
|
Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs
Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
2.99 mg/L
Compound: Linezolid
|
Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs
Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs
|
[PMID: 20385852] |
| THP-1 | EC50 |
8.45 mg/L
Compound: Linezolid
|
Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs
Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs
|
[PMID: 20385852] |
| Vero | IC50 |
>200 μg/mL
Compound: Linezolid
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30145051] |
| Vero | IC50 |
>64 μg/mL
Compound: Linezolid
|
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 28523106] |
| Vero | IC50 |
>64 μg/mL
Compound: Linezolid
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32666789] |
| Vero | IC50 |
>64 μg/mL
Compound: Linezolid
|
Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by MTT assay
|
[PMID: 39236219] |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 165800-03-3
-
Appearance Solid
-
Molecular Weight 337.35
-
Formula C16H20FN3O4
-
Color White to off-white
-
SMILES
O=C(O[C@H]1CNC(C)=O)N(C1)C2=CC(F)=C(N3CCOCC3)C=C2
-
Synonyms
PNU-100766
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (54)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Prodrug florfenicol amine is activated by intrinsic resistance to target Mycobacterium abscessus. [Abstract]2025 Nov;10(11):2875-2891. PMID: 41168430
Linezolid purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]
Dose-response curves for Linezolid (LZD: 0.0625-256 μg/mL) against M. abscessus ∆eis2 or M. abscessus Eis2 T258R strains complemented with pOLYG-aac(3)IV-eis2 overexpression or pOLYG-aac(3)IV control vector.
Linezolid purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]
Efficacy of CLR, Linezolid (LZD: 100 mg/kg) and FF-NH2 versus saline vehicle in an acute mouse infection model. GM-CSF KO mice were infected with M. abscessus WT, treatment began on day 2 and continued for 9 days (CLR/LZD oral daily, FF-NH2 subcutaneous twice daily). Bacterial burden (colony forming units (c.f.u.)) was measured in lung, liver and spleen at day 12 post-infection.
-
-
Int J Biol Macromol
The combination of insulin and linezolid ameliorates Staphylococcus aureus pneumonia in individuals with diabetes via the TLR2/MAPKs/NLRP3 pathway. [Abstract]2023 Jul 1;242(Pt 1):124750. PMID: 37160172
Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]
MH-S cells were pretreated with insulin, linezolid, or combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4, high glucose and/or S. aureus DU1090 for 4 h, then the cell viability was tested by CCK8 kit;
Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]
MH-S cells were pretreated with insulin, linezolid, or a combination of insulin (50 nmol/L) and linezolid (0.25 μg/ml) for 1 hour, and then treated with high glucose (30 mmol/L) and/or Staphylococcus aureus 8325-4, or high glucose and/or Staphylococcus aureus DU1090 for 4 hours. The glucose content in the MH-S cell culture medium was detected using a glucose content detection kit.
Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]
MH-S cells were pretreated with insulin, linezolid and combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4 (1 × 107 CFUs), high glucose and/or S. aureus DU1090 (1 × 107 CFUs) for 4 h. Then the expressions of TLR2, MAPKs (JNK, ERK, p38, p-JNK, p-ERK1/2, and p-p38), NLRP3 inflammasome proteins (NLRP3, ASC, Caspase-1, IL-1β, IL-18) and MIP-2 were detected by each pathway inhibitor treatment was used to further explore the upstream and downstream relationships among TLR2, MAPKs and NLRP3-related inflammatory pathways in MH-S cells.
-
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Pharmaceutics
Antibacterial Activity of Linezolid against Gram-Negative Bacteria: Utilization of ε-Poly-l-Lysine Capped Silica Xerogel as an Activating Carrier. [Abstract]2020 Nov 21;12(11):1126. PMID: 33233423 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127 -
Virulence
Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]2024 Dec;15(1):2415952. PMID: 39390774 -
Microb Biotechnol
Attenuator LRR - a regulatory tool for modulating gene expression in Gram-positive bacteria. [Abstract]2021 Nov;14(6):2538-2551. PMID: 33720523 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365 -
Drug Des Devel Ther
Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation. [Abstract]2018 Jun 11:12:1679-1684. PMID: 29928111 -
Bioorg Chem
2026 Mar:170:109493. PMID: 41547038 -
Int J Antimicrob Agents
A new perspective on the antimicrobial mechanism of linezolid against Staphylococcus aureus revealed by proteomics and metabolomics analysis. [Abstract]2025 Jun;65(6):107470. PMID: 40049374 -
Microb Genom
Uncovering resistance pathways to first- and last-line antibiotics in Mycobacterium tuberculosis populations. [Abstract]2026 May;12(5):001723. PMID: 42154617 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 May 23:e0024925. PMID: 40407337 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980 -
Antimicrob Agents Chemother
2024 Oct 29:e0094524. PMID: 39470202 -
Front Microbiol
Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China. [Abstract]2023 Apr 26:14:1131178. PMID: 37180277 -
Antimicrob Agents Chemother
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. [Abstract]2023 Apr 18;67(4):e0165522. PMID: 36920191 -
Antimicrob Agents Chemother
Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. [Abstract]2021 Mar 18;65(4):e01445-20. PMID: 33495223 -
Front Microbiol
Radezolid Is More Effective Than Linezolid Against Planktonic Cells and Inhibits Enterococcus faecalis Biofilm Formation. [Abstract]2020 Feb 14;11:196. PMID: 32117185 -
Front Microbiol
Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study. [Abstract]2018 Sep 7:9:2095. PMID: 30245674 -
ACS Omega
In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. [Abstract]2025 Oct 27;10(44):52289-52295. PMID: 41244472 -
ACS Omega
In Vitro Inhibition of Growth, Biofilm Formation, and Persisters of Staphylococcus aureus by Pinaverium Bromide. [Abstract]2023 Mar 6;8(10):9652-9661. PMID: 36936302 -
ACS Omega
Antibacterial and Antibiofilm Activities of Sertindole and Its Antibacterial Mechanism against Staphylococcus aureus. [Abstract]2023 Feb 3;8(6):5415-5425. PMID: 36816695 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
iScience
Cinacalcet exhibits rapid bactericidal and efficient anti-biofilm activities against multidrug-resistant Gram-positive pathogens. [Abstract]2023 Mar 11;26(4):106378. PMID: 37034999 -
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
ACS Infect Dis
Repurposing GSK2018682 Confers Dual Antibacterial and Antibiofilm Activity against Staphylococcus aureus. [Abstract]2026 Feb 13;12(2):623-636. PMID: 41525229 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
ACS Infect Dis
Derazantinib Inhibits the Planktonic Growth and Biofilm Formation of Staphylococcus aureus by Binding Membrane Phospholipids and Disrupting the Cell Membrane. [Abstract]2025 Jun 13;11(6):1473-1485. PMID: 40367508 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 May 19:e0307424. PMID: 40387379 -
ACS Infect Dis
Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]2024 Aug 9;10(8):2961-2977. PMID: 39066703 -
Microbiol Spectr
Protective effect of Enterococcus faecium against ethanol-induced gastric injury via extracellular vesicles. [Abstract]2024 Apr 2;12(4):e0389423. PMID: 38488394 -
ACS Infect Dis
Thiazolopyrimidinone Derivative H5-23 Enhances Daptomycin Activity against Linezolid-Resistant Enterococcus faecalis by Disrupting the Cell Membrane. [Abstract]2023 Dec 8;9(12):2523-2537. PMID: 38014911 -
Microbiol Spectr
Clemastine Inhibits the Biofilm and Hemolytic of Staphylococcus aureus through the GdpP Protein. [Abstract]2022 Apr 27;10(2):e0054121. PMID: 35234502 -
Microbiol Spectr
The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]2022 Feb 23;10(1):e0099121. PMID: 35019708 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
Microb Pathog
In vitro evaluation of the antibacterial activities of radezolid and linezolid for Streptococcus agalactiae. [Abstract]2020 Feb;139:103866. PMID: 31715321 -
Thromb Res
Linezolid impair proplatelet formation by reducing mitochondrial energy metabolism in MEG-01 cells. [Abstract]2025 Sep 22:255:109498. PMID: 41005026 -
Dis Model Mech
An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor. [Abstract]2021 Dec 1;14(12):dmm049145. PMID: 34643222 -
Infect Drug Resist
In Vitro Activity of Vancomycin, Teicoplanin, Linezolid and Daptomycin Against Methicillin-Resistant Staphylococcus aureus Isolates Collected from Chinese Hospitals in 2018-2020. [Abstract]2021 Dec 16;14:5449-5456. PMID: 34949928 -
J Antibiot (Tokyo)
Antibacterial effects of BB-Cl-Amidine against multidrug-resistant Gram-positive pathogens via membrane disruption. [Abstract]2025 Oct 9. PMID: 41068498 -
Eur J Clin Pharmacol
Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains. [Abstract]2021 Jan;77(1):79-86. PMID: 32812063 -
J Antibiot
2020 Dec;73(12):845-851. PMID: 32678335 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Rapid Commun Mass Spectrom
2025;39(20):e10103. PMID: 40589310 -
Biol Pharm Bull
Development of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Simultaneous Determination of Linezolid and Tedizolid in Human Plasma. [Abstract]2022;45(4):421-428. PMID: 35370266 -
Pol J Microbiol
Mechanisms of Rapid Bactericidal and Anti-Biofilm Alpha-Mangostin In Vitro Activity against Staphylococcus aureus. [Abstract]2023 Jun 14;72(2):199-208. PMID: 37314356 -
-
-
-
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (296.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. [Content Brief]
[2]. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. [Content Brief]
[3]. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. [Content Brief]
[4]. He MZ, Jiang YW, Cai C. Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. [Content Brief]
[5]. Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice. Antimicrob Agents Chemother. 2012 Jul 30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9643 mL | 14.8214 mL | 29.6428 mL | 74.1070 mL |
| 5 mM | 0.5929 mL | 2.9643 mL | 5.9286 mL | 14.8214 mL | |
| 10 mM | 0.2964 mL | 1.4821 mL | 2.9643 mL | 7.4107 mL | |
| 15 mM | 0.1976 mL | 0.9881 mL | 1.9762 mL | 4.9405 mL | |
| 20 mM | 0.1482 mL | 0.7411 mL | 1.4821 mL | 3.7054 mL | |
| 25 mM | 0.1186 mL | 0.5929 mL | 1.1857 mL | 2.9643 mL | |
| 30 mM | 0.0988 mL | 0.4940 mL | 0.9881 mL | 2.4702 mL | |
| 40 mM | 0.0741 mL | 0.3705 mL | 0.7411 mL | 1.8527 mL | |
| 50 mM | 0.0593 mL | 0.2964 mL | 0.5929 mL | 1.4821 mL | |
| 60 mM | 0.0494 mL | 0.2470 mL | 0.4940 mL | 1.2351 mL | |
| 80 mM | 0.0371 mL | 0.1853 mL | 0.3705 mL | 0.9263 mL | |
| 100 mM | 0.0296 mL | 0.1482 mL | 0.2964 mL | 0.7411 mL |